Single Islet Cell Infusion Success


By: Elka Karl

A joint study by the University of Minnesota and the University of California San Francisco, with one islet cell infusion from a single donor pancreas, has achieved insulin independence in four of six people with longterm type 1 diabetes.

Four recipients have been insulin independent for more than one year; three for over two years, and two for more than three years.

A new type of anti-rejection treatment was developed and administered in the trial. A new generation of anti-CD3 monoclonal antibody was administered in this study during the first two weeks after transplant. This antibody targets the type of white blood cells that cause type 1 diabetes and mediate rejection of transplants.

Study participants received two other immune-suppression drugs. Current studies are testing whether the longterm maintenance immune-suppression medication can be minimized or even discontinued in islet cell recipients given the anti-CD3 antibody.

The study’s success can be attributed to better islet cell preparation and optimized anti-rejection drugs, according to the researchers.

-Diabetes Care, March 2004



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.